Clostridium Butyricum for Motor and Non-motor Symptoms in Parkinson's Disease
📖 Wiki Page
clinical_trial661 wordssynced 2026-04-02
Clostridium Butyricum for Motor and Non-motor Symptoms in Parkinson's Disease
Trial Overview
flowchart TD
Clostridium_Butyricum_for_Moto["Clostridium Butyricum for Motor and Non-motor Sy"] -->|"references"| BDNF["BDNF"]
Clostridium_Butyricum_for_Moto["Clostridium Butyricum for Motor and Non-motor Sy"] -->|"references"| HDAC["HDAC"]
style Clostridium_Butyricum_for_Moto fill:#4fc3f7,stroke:#333,color:#000
| Field | Value | |-------|-------| | NCT Number | [NCT06548256](https://clinicaltrials.gov/study/NCT06548256) | | Status | Recruiting | | Sponsor | Pusan National University (Korea) | | Phase | Not specified | | Intervention | Miyarisan-BM (Clostridium Butyricum Miyairi) |
Mechanism
[Clostridium butyricum](https://en.wikipedia.org/wiki/Clostridium_butyricum) is a butyrate-producing gut bacterium that has been studied for its beneficial effects on gut health and inflammation. The proposed mechanisms in Parkinson's disease include:
Butyrate production: Produces butyrate, a short-chain fatty acid with anti-inflammatory properties
Gut barrier integrity: Strengthens the intestinal epithelial barrier, reducing leaky gut
Modulation of gut microbiome: Promotes beneficial bacteria and reduces pathogenic species
Immune modulation: Reduces systemic inflammation through regulatory T-cell activation
Gut-brain axis: May influence brain function through vagal nerve signaling and systemic inflammation reduction
Rationale
...
Clostridium Butyricum for Motor and Non-motor Symptoms in Parkinson's Disease
Trial Overview
Mermaid diagram (expand to render)
| Field | Value | |-------|-------| | NCT Number | [NCT06548256](https://clinicaltrials.gov/study/NCT06548256) | | Status | Recruiting | | Sponsor | Pusan National University (Korea) | | Phase | Not specified | | Intervention | Miyarisan-BM (Clostridium Butyricum Miyairi) |
Mechanism
[Clostridium butyricum](https://en.wikipedia.org/wiki/Clostridium_butyricum) is a butyrate-producing gut bacterium that has been studied for its beneficial effects on gut health and inflammation. The proposed mechanisms in Parkinson's disease include:
Butyrate production: Produces butyrate, a short-chain fatty acid with anti-inflammatory properties
Gut barrier integrity: Strengthens the intestinal epithelial barrier, reducing leaky gut
Modulation of gut microbiome: Promotes beneficial bacteria and reduces pathogenic species
Immune modulation: Reduces systemic inflammation through regulatory T-cell activation
Gut-brain axis: May influence brain function through vagal nerve signaling and systemic inflammation reduction
Rationale
The [gut-brain axis](/mechanisms/gut-immune-brain-axis-parkinsons) plays a critical role in Parkinson's disease pathogenesis. Many PD patients exhibit gut dysfunction years before motor symptoms appear. Gut inflammation and dysbiosis may contribute to alpha-synuclein aggregation in the enteric nervous system, which then propagates to the central nervous system via the vagus nerve.
Clostridium butyricum supplementation represents a targeted approach to:
Reduce gut inflammation
Restore microbiome balance
Improve gut barrier function
Potentially slow alpha-synuclein propagation
Butyrate and Neurodegeneration
The Butyrate Molecule
[Butyrate](/mechanisms/short-chain-fatty-acids-neurodegeneration) is a four-carbon short-chain fatty acid (SCFA) produced by bacterial fermentation of dietary fiber in the colon[@butyrate2023]. It serves as:
Primary energy source for colonocytes
Histone deacetylase (HDAC) inhibitor: Epigenetic regulation of gene expression
Anti-inflammatory agent: Modulates immune cell function
Barrier enhancer: Strengthens gut tight junctions
Butyrate's Effects on the Brain
The mechanisms by which butyrate may influence neurodegenerative processes include:
[Gut-Immune-Brain Axis in Parkinson's Disease](/mechanisms/gut-immune-brain-axis-parkinsons)
[Microbiome-Targeted Interventions for PD](/therapeutics/microbiome-gut-brain-axis-parkinsons)
[Bacillus Subtilis for PD](/clinical-trials/bacillus-subtilis-pd)
[Probiotic Depression in PD](/clinical-trials/probiotic-depression-parkinsons-nct05568498)
[Short-Chain Fatty Acids in Neurodegeneration](/mechanisms/short-chain-fatty-acids-neurodegeneration)
References
[The Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson's Disease - NCT06548256](https://clinicaltrials.gov/study/NCT06548256)
[Gut-Brain Axis in Parkinson's Disease - NeuroWiki](/mechanisms/gut-immune-brain-axis-parkinsons)
[Microbiome and Parkinson's Disease Research](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047919/)
[Butyrate and neurodegenerative diseases: Mechanisms and therapeutic potential (2023)](https://doi.org/10.3389/fnins.2023.1156890)
[Gut-brain axis in Parkinson's disease: A comprehensive review (2024)](https://doi.org/10.1186/s12974-024-03089-3)
[Gut microbiome dysbiosis in Parkinson's disease: Current understanding and therapeutic implications (2023)](https://doi.org/10.1002/mds.29509)